Dimension Therapeutics

company

About

Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$65M
Industries
Biotechnology,Genetics,Medical,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.

The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.

In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$65M
Dimension Therapeutics has raised a total of $65M in funding over 2 rounds. Their latest funding was raised on Apr 21, 2015 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 21, 2015 Series B $65M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Dimension Therapeutics is funded by 1 investors. Tourbillon Global Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Tourbillon Global Ventures Series B